Chrysalis Biotherapeutics

Saving Lives
Through Innovation

Developing Next Generation Regenerative Peptide Drugs

Chrysalis is pioneering the use of natural regenerative peptides to restore vascular function and activate normal stem cell populations where they exist in the body to accelerate tissue repair and prevent damaging effects of trauma, disease, ischemia, and radiation exposure

Closeup of brain MRI scan result

Solution for Radiation Induced Tissue Damage

Development of drugs to selectively reduce radiotherapy-induced normal tissue damage may improve post-therapy quality of life and save lives.

nuclear_explosion_chrysbio

Solution for Nuclear Radiation Exposure

A single TP508 injection 24 hours after a lethal dose of whole body radiation significantly increases survival and reduces delayed effects of radiation.

Screen Shot 2019-12-12 at 2.46.16 PM

TP508 Peptide Technology

The TP508 thrombin peptide is released locally following vascular injury to initiate cellular regenerative processes that lead to revascularization, stem cell activation, and tissue repair.

Coroanvirus covid-19 sars 2019 ncov 2 virus microscope view. 3d illustration

Covid-19

TP508, targets endothelial cells to restore vascular function and modulate immune responses
after injury. A single injection of TP508 24 hours after SARS-CoV-2 infection almost completely
blocks the CoV-2 virus-induced cytokine storm in animal models.

TP-508 Clinical Pipeline

INDICATION Pre-Clinical
Studies
IND Enabling
Studies/cGMP
Manufacturing
Phase 1/2
Moderate/Severe Covid-19
Brain Cancer Radiation Therapy
Traumatic Brain Injury
Nuclear Countermeasure/Acute
Exposure

Latest Press Releases